539PProfiling of immune related adverse events from nivolumab or pembrolizumab monotherapy in advanced non-small cell lung cancer in real world. (25th November 2018) - Aso, M; Sugawara, S; Toi, Y; Sugisaka, J; Ono, H; Tsurumi, K; Suzuki, K; Shimizu, H; Domeki, Y; Aiba, T; Kawana, S; Saito, R; et al.